Taysha Gene Therapies, Inc.
News
(2)April 2026
TSHA files amendment to correct and update prior SEC statements
**⚠️ Important Notice:** The provided input only contains the metadata for an SEC filing (`d942601dars.pdf`) but does not include the actual document text or PDF content. Therefore, I cannot summarize the specific details, financials, or commentary. However, as an expert financial analyst, I have p
TSHA details governance and board structure for annual shareholder meeting
# 📑 What This Document Is ✉️ This document is a Proxy Statement (DEF 14A), which is essentially a mandatory informational packet sent by Taysha Gene Therapies, Inc. to its stockholders. Think of it as the company's formal homework assignment for its annual shareholder meeting. 👉 Why it matters: T
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.